In Q4, Eli Lilly reported EPS at $5.32, up from $2.49 in the same quarter last year. This print beat analysts’ estimates by 4.7%. Over the next 12 months, Wall Street expects Eli Lilly’s full ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue ...